Clinical Trial: Efficacy and Safety of First-Line Therapy with Gemox Chemotherapy Combined with Lenvatinib and Iparomlimab and Tuvonralimab in Patients with Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma (China)

China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of First-Line Therapy with Gemox Chemotherapy Combined with Lenvatinib and Iparomlimab and Tuvonralimab in Patients with Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132618

Registration Time: 2026/09/16

Type: Interventional study

Primary Sponsor: West China Hospital, Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336679

Published by HT Digital Content Services with permission from Health Daily Digest....